Please login to the form below

Not currently logged in
Email:
Password:

MEDI1814

This page shows the latest MEDI1814 news and features for those working in and with pharma, biotech and healthcare.

Biogen rises on more positive data for Alzheimer's candidate

Biogen rises on more positive data for Alzheimer's candidate

compounds. Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,

Latest news

  • Lilly taps AstraZeneca for another anti-amyloid drug Lilly taps AstraZeneca for another anti-amyloid drug

    Lilly taps AstraZeneca for another anti-amyloid drug. MEDI1814 could potentially slow the progression of Alzheimer's. ... Lilly and AZ will collaborate on the development of MEDI1814, an antibody against amyloid-beta 42 (Aβ42), which is currently in

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics